Efficacy and safety of intensified induction, autologous stem cell transplantation, consolidation and maintenance therapy in patients with newly diagnosed multiple myeloma: a phase2 study

Trial Profile

Efficacy and safety of intensified induction, autologous stem cell transplantation, consolidation and maintenance therapy in patients with newly diagnosed multiple myeloma: a phase2 study

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 30 Sep 2016

At a glance

  • Drugs Lenalidomide (Primary) ; Bortezomib; Cyclophosphamide; Dexamethasone; Melphalan
  • Indications Multiple myeloma
  • Focus Therapeutic Use
  • Acronyms JSCT-MM14
  • Most Recent Events

    • 26 Sep 2016 Status changed from recruiting to active, no longer recruiting.
    • 03 Aug 2015 Planned initiation date changed from 1 Jul 2015 to 28 Jul 2015 as reported by University Hospital Medical Information Network - Japan.
    • 15 Jul 2015 Status changed from not yet recruiting to recruiting as reported by University Hospital Medical Information Network - Japan.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top